These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 17889411)
21. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217 [TBL] [Abstract][Full Text] [Related]
22. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Ansaldi F; Canepa P; Parodi V; Bacilieri S; Orsi A; Compagnino F; Icardi G; Durando P Vaccine; 2009 May; 27(25-26):3345-8. PubMed ID: 19200846 [TBL] [Abstract][Full Text] [Related]
23. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Tsai TF; Crucitti A; Nacci P; Nicolay U; Della Cioppa G; Ferguson J; Clemens R Scand J Infect Dis; 2011 Sep; 43(9):702-6. PubMed ID: 21534891 [TBL] [Abstract][Full Text] [Related]
24. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Lapi F; Marconi E; Simonetti M; Baldo V; Rossi A; Sessa A; Cricelli C Expert Rev Vaccines; 2019 Jun; 18(6):663-670. PubMed ID: 31155968 [No Abstract] [Full Text] [Related]
25. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980 [TBL] [Abstract][Full Text] [Related]
26. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. Fenoglio D; Zocchi MR; Parodi A; Durando P; Gabutitp G; Gasparini R; Poggi A J Prev Med Hyg; 2011 Sep; 52(3):137-41. PubMed ID: 22010544 [TBL] [Abstract][Full Text] [Related]
27. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. Nichol KL; Nordin J; Mullooly J; Lask R; Fillbrandt K; Iwane M N Engl J Med; 2003 Apr; 348(14):1322-32. PubMed ID: 12672859 [TBL] [Abstract][Full Text] [Related]
28. Influenza vaccine with squalene adjuvant: new preparation. No better than available products. Prescrire Int; 2004 Dec; 13(74):206-8. PubMed ID: 15599987 [TBL] [Abstract][Full Text] [Related]
29. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. Tsai T; Kyaw MH; Novicki D; Nacci P; Rai S; Clemens R Vaccine; 2010 Feb; 28(7):1877-80. PubMed ID: 19969117 [TBL] [Abstract][Full Text] [Related]
31. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. O'Hagan DT Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151 [TBL] [Abstract][Full Text] [Related]
32. Comparison of two vaccination programmes in preventing influenza-related hospitalization among the elderly during two consecutive seasons. Honkanen P; Läärä E; Pyhälä R; Kivelä SL; Helena Mäkelä P Scand J Infect Dis; 2006; 38(6-7):506-11. PubMed ID: 16798702 [TBL] [Abstract][Full Text] [Related]
33. Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. Voordouw BC; Sturkenboom MC; Dieleman JP; Stijnen T; van der Lei J; Stricker BH Arch Intern Med; 2006 Oct; 166(18):1980-5. PubMed ID: 17030831 [TBL] [Abstract][Full Text] [Related]
34. [Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain]. Pérez-Rubio A; Eiros JM Rev Esp Quimioter; 2018 Feb; 31(1):43-52. PubMed ID: 29355006 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V ® and Fluad ® ) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. Gasparini R; Amicizia D; Lai PL; Rossi S; Panatto D Hum Vaccin Immunother; 2013 Jan; 9(1):144-52. PubMed ID: 23143775 [TBL] [Abstract][Full Text] [Related]
36. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Jackson LA; Jackson ML; Nelson JC; Neuzil KM; Weiss NS Int J Epidemiol; 2006 Apr; 35(2):337-44. PubMed ID: 16368725 [TBL] [Abstract][Full Text] [Related]
37. Influenza vaccine effectiveness among elderly persons living in the community during the 2003--2004 season. Hara M; Sakamoto T; Tanaka K Vaccine; 2008 Nov; 26(50):6477-80. PubMed ID: 18573296 [TBL] [Abstract][Full Text] [Related]
39. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Iob A; Brianti G; Zamparo E; Gallo T Epidemiol Infect; 2005 Aug; 133(4):687-93. PubMed ID: 16050515 [TBL] [Abstract][Full Text] [Related]
40. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]